Trending: GSK Buys Bellus Health for About $2 Billion
18 Abril 2023 - 5:30AM
Noticias Dow Jones
0959 GMT - GSK is among the most mentioned companies across news
items over the past six hours, according to Factiva data, after it
said it had reached an agreement to buy Canadian late-stage
biopharmaceutical company Bellus Health Inc. for $14.75 a share in
cash, representing a total equity value of around $2.0 billion. The
British pharma major said that through the acquisition it will gain
access to camlipixant, a treatment for refractory chronic cough
which is currently in phase III development. Accretion to adjusted
earnings per share from the acquisition is expected to occur from
2027. It has the potential to deliver significant sales through
2031 and beyond, according to GSK. Dow Jones & Co. owns
Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
April 18, 2023 06:15 ET (10:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
BELLUS Health (NASDAQ:BLU)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
BELLUS Health (NASDAQ:BLU)
Gráfica de Acción Histórica
De May 2023 a May 2024